<div id="readability-page-1"><p>Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of &#34;Hold&#34; from the thirty brokerages that are  covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and nine have issued  a buy recommendation on  the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $33.68.</p><div><p><span></span><span>Get <strong>Sarepta Therapeutics</strong> alerts:</span></p></div><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>A number of research analysts have weighed in on SRPT shares. Bank of America upped their price objective on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an &#34;underperform&#34; rating in a research report on Wednesday, October 22nd. Leerink Partners lifted their price target on Sarepta Therapeutics from $12.00 to $15.00 and gave the company a &#34;market perform&#34; rating in a research note on Tuesday, September 9th. Wells Fargo &amp; Company reduced their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an &#34;overweight&#34; rating for the company in a report on Wednesday, November 5th. Wall Street Zen lowered Sarepta Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada boosted their price objective on Sarepta Therapeutics from $14.00 to $16.00 and gave the company a &#34;sector perform&#34; rating in a research report on Wednesday, October 8th.</p><p><b>Get Our Latest Research Report on SRPT</b></p><h2>Sarepta Therapeutics Trading Up 3.5%</h2><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p>Shares of NASDAQ:SRPT opened at $22.31 on Wednesday. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics has a 12-month low of $10.41 and a 12-month high of $129.84. The business has a 50 day moving average of $20.88 and a two-hundred day moving average of $20.64. The company has a market capitalization of $2.34 billion, a PE ratio of -7.41 and a beta of 0.54. </p><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm had revenue of $399.36 million for the quarter, compared to analysts' expectations of $331.51 million. During the same period last year, the firm earned $0.62 earnings per share. Sarepta Therapeutics's revenue for the quarter was down 14.5% compared to the same quarter last year.  As a group, analysts forecast that  Sarepta Therapeutics will post 2.67 EPS for the current year. </p><h2>Hedge Funds Weigh In On Sarepta Therapeutics</h2><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>A number of large investors have recently added to or reduced their stakes in SRPT. Ancora Advisors LLC grew its position in shares of  Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 300 shares during the period.  Brooklyn Investment Group raised its position in shares of  Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock valued at $46,000 after buying an additional 590 shares during the last quarter.  Banque Transatlantique SA purchased a new position in  Sarepta Therapeutics in the 1st quarter worth approximately $44,000.  iSAM Funds UK Ltd acquired a new stake in shares of  Sarepta Therapeutics in the third quarter valued at approximately $25,000.  Finally, Byrne Asset Management LLC purchased a new position in  Sarepta Therapeutics during the third quarter worth approximately $33,000. 86.68% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Sarepta Therapeutics Company Profile</h2> (Get Free Report)<p>Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.</p><h2>See Also</h2><ul><li>Five stocks we like better than Sarepta Therapeutics</li><li>What is Short Interest? How to Use It</li><li>Why Taiwan Semiconductor's 6.5% Dip Could Be a Smart Buy</li><li>Growth Stocks: What They Are, What They Are Not</li><li>RTX Surges to Record Highs as Defense Orders Explode</li><li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li><li>Smart Money Is Buying Auto Suppliers, Not Car Brands</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sarepta Therapeutics Right Now?</h2><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p><p>While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SRPT

<p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has received an average "Hold" rating from 30 brokerages. Analysts have mixed opinions: 6 recommend selling, 15 suggest holding, and 9 advise buying. The average 12-month price target is $33.68. Recent analyst actions include price target adjustments by Bank of America, Leerink Partners, Wells Fargo, and Royal Bank of Canada. The stock opened at $22.31, with a market cap of $2.34 billion. Institutional investors hold 86.68% of shares. Sarepta focuses on RNA-targeted therapeutics for rare diseases.</p>

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Recommendation of "Hold" by Brokerages